Background. Evidence from animal models supports the hypothesis that dysregulated transforming growth factor b 1 (TGFb 1 ) expression plays a role in chronic allograft rejection, the progression of diabetic nephropathy and ®brotic glomerulopathies. However, more evidence is required to support this hypothesis in man, and the current literature concerning blood TGFb 1 levels in clinical studies is highly confused. We have investigated: (i) the hypothesis that the widespread practice of activating clinical samples prior to measurement of TGFb 1 is detecting the platelet-released pool of TGFb 1 , artefactually generated on venepuncture and unrepresentative of the real circulating in vivo TGFb 1 pool; and (ii) the effect of different immunosuppressive drugs on apparent TGFb 1 plasma levels. Methods. The effect of two different venepuncture procedures on plasma TGFb 1 was compared in 10 healthy volunteers, one procedure designed to minimize platelet activation and the other representing standard venepuncture practice in a clinic situation. Blood samples from 52 renal transplant recipients on either cyclosporine or tacrolimus immunosuppression were taken by standard venepuncture to investigate the effect of immunosuppressive drugs on plasma TGFb 1 . Plasma TGFb 1 and b thromboglobulin were measured by ELISA. Results. Among 10 healthy volunteers who underwent two different methods of venepuncture, eight of 10 had undetectable levels of TGFb 1 (-100 pguml) under conditions that minimize platelet activation. In contrast, all 10 paired plasma samples collected by vacutainer had measurable TGFb 1 (median 7.70 nguml, interquartile range 5.87±13.64 nguml) following acidu urea activation. The median bTG level (a measure of platelet degranulation) was 0.71 mguml (interquartile range 0.53±1.19 mguml) in the special collections compared with 3.39 mguml (interquartile range 2.27±4.33 mguml) in the vacutainer samples (Ps0.0029).
Introduction
There is little doubt that TGFb 1 is pro®brotic in many disease conditions. In an experimental model, persistent expression of active TGFb 1 in the vasculature promotes ®brosis in the kidney w1x. Neutralizing the effects of TGFb 1 in experimental models with natural antagonist w2x protects against the development of tissue ®brosis.
Clinical studies of ®brotic disease have measured circulating blood levels of TGFb 1 in patients and healthy individuals to investigate the link between TGFb 1 expression and the clinical presentation and prognosis of disease. A highly confused literature on blood levels of TGFb 1 has developed with claims that values in normal controls are low w3x or high w4x, that certain drugs induce high levels of circulating TGFb 1 w5x, and that patients in end-stage renal failure (ESRF), in particular African Americans w6x, have high levels of circulating TGFb 1 .
Attention has been drawn recently to the dif®culties involved in interpretation of data on TGFb 1 blood levels w7x. The complex interaction of factors including the choice of blood sample (serum or plasma), the deliberate sample activation, the technical measurement of TGFb 1 by ELISA, and the presence of latent and active pools of TGFb 1 have a profound in¯uence on the interpretation of TGFb 1 levels in a clinical context. The fundamental problem in estimating a real in vivo circulating level of TGFb 1 is how to avoid the enormous platelet pool of readily releasable TGFb 1 . TGFb 1 was originally isolated from platelets w8x, where it is stored at high concentration as a latent complex. Most of the confusion in the literature relates to whether or not researchers adopt a strategy to avoid, minimize or control for platelet-released TGFb 1 occurring in the sample ex vivo.
The choice of serum as the medium in which to quantitate TGFb 1 seems particularly inappropriate for two reasons. First, there is a signi®cant correlation between the total platelet count and TGFb 1 levels w9x (measured after activation of the latent molecule, see below), which is common to other platelet-stored proteins e.g. b-thromboglobulin w10x. Secondly, it has been demonstrated that 95% of the TGFb 1 in serum is artefactually derived from platelets on blood clotting w3x. This accounts for serum TGFb 1 levels being reported as 10-to 20-fold w11x, 20-fold w3x and 3.84-fold w9x higher than plasma levels. TGFb 1 levels in plasma (measured after activation of the latent molecule and often referred to as total level) have also been reported by workers in clinical studies of TGFb 1 expression as representing a circulating blood level w3x. The recommendation that plasma TGFb 1 levels should be related to the level of a recognized platelet release protein (b thromboglobulin or platelet factor 4) has unfortunately not been adopted as standard practice w3x. Workers who recognize the danger of platelet-released TGFb 1 recommend the use of platelet poor plasma w12x, but this does not address or control for the variable platelet release of proteins that occurs during the trauma of venepuncture.
This study is therefore designed (i) to illustrate the effect of venepuncture on the non-speci®c release of TGFb 1 from platelets at the point of blood collection, and (ii) to demonstrate how a failure to correct for platelet activation can lead to erroneous conclusions about the effect of different immunosuppressive drugs on plasma TGFb 1 expression. This study is not designed to recommend the optimum method of venepuncture or quantitation of plasma TGFb 1 , but is investigating the effects of two important modulators of platelet activation (trauma at venepuncture and drug-platelet effects) on the subsequent measurement of plasma TGFb 1 after deliberate sample activation and how these impact on our interpretation of TGFb 1 biology in renal transplantation.
Subjects and methods
The effect of venepuncture: the healthy volunteer group Ten healthy volunteers (mean age"SEM 34.4"2.3 years; 7 males, 3 females; 9 Caucasions, 1 non-Caucasion) were subjected to two venepunctures from two different sites on the same occasion by both the special procedure and the standard procedure. Informed consent was obtained for venepuncture.
Special venepuncture procedure
This procedure is recommended to minimize platelet activation during venepuncture w12x. Blood samples were collected from healthy volunteers without the use of a tourniquet by introducing a wide bore (16 gauge needle) into the antecubital vein with minimal trauma and allowing blood tō ow slowly without suction from syringe or vacutainer into a pre-chilled EDTA bottle. Samples were separated immediately by centrifugation at 1200 g for 10 min and the plasma aliquots were stored at À708C.
Standard venepuncture
Blood samples were collected from healthy volunteers using a tourniquet by venepuncture with a 21 gauge needle and vacutainer blood collection system (Becton and Dickenson, Oxford, UK). Blood was collected into EDTA tubes and plasma was immediately separated by centrifugation at 1200 g for 10 min, and plasma aliquots were stored frozen at À70 8C. Thus, trauma during venepuncture was the only difference in the procedure for obtaining plasma samples from normal volunteers.
The effect of immunosuppressive drugs: the allograft recipients
Blood samples from 52 patients (mean age"SEM 44.2"2.0 years; 35 males, 17 females; 44 Caucasion, 8 non-Caucasians) undergoing renal transplantation at Manchester Royal In®rmary were obtained by standard venepuncture procedure as part of normal clinical follow up and monitoring of graft function. Samples were separated within 3 h by centrifugation at 1200 g and storage at À708C. Thirty-two patients were receiving cyclosporine-based immunosuppression with a mean drug trough level of 156 nguml, range 64±275 nguml (monotherapy or combined with steroids and azathioprine), and 20 patients received tacrolimus monotherapy with a mean drug trough level of 13 nguml, range 8±36 nguml. In the total patient group, the methods of venepuncture and sample preparation were kept constant (and were typical of those employed widely in clinical practice) to allow comparison of the effects of immunosuppressive drugs on TGFb 1 levels.
Aciduurea activation of plasma TGFb 1
The method was based on the R&D Systems (Abingdon, UK) procedure from the Quantikine Immunoassay kit. To 100 ml of plasma, 100 ml of 2.5 N acetic acidu10 M urea were added, mixed and incubated for 10 min at room temperature. The samples were neutralized by adding 100 ml of 2.7 N NaOHu1 M HEPES and added to the assay plate within 15 min of activation.
Acid activation of plasma TGFb 1
One-and-a-half microlitres of 6 M HCl was added to 100 ml of plasma and incubated for 15 minutes at room temperature. Samples were neutralized to pH 7.0±7.4 with~3.0 ml of neutralizing buffer (50% voluvol 1 M HEPESu6 M NaOH).
Immunoassay for TGFb 1
The in-house assay has been described in detail w13x. Brie¯y, the capture antibody was a monoclonal to TGFb 1,2,3 .
(Genzyme, Framingham, USA, clone 1D11) and the detection antibody was a chicken polyclonal antibody speci®c to TGFb 1 (R&D Systems), followed by peroxidase conjugated donkey anti-chicken Ig (Jackson Labs, Stratch, Luton, UK). Signal was generated by the addition of Amerlite substrate (Johnson and Johnson Clinical Diagnostics, Ascot, UK) and read on a Microlumat LB96P luminometer (EG&G Berthold, Leeds, UK). Data was analysed using Mikrowin software.
Assay for b thromboglobulin (bTG)
An ELISA for bTG was employed using the principle of competition between soluble bTG in plasma and solid phase bTG coated onto an ELISA plate for a limited amount of anti-bTG antibody added to the samples. Puri®ed bTG (Novabiochem Ltd, Nottingham, UK) was coated onto ELISA plates at 200 nguml in 100 ml of 0.1 M sodium bicarbonateucarbonate buffer, pH 9.6 for 16 h. After washing, the plates were blocked with 5% bovine serum albumin (BSA) for 1 h. Plasma samples were diluted 1 : 25 with assay buffer (5% BSA in PBS with 0.05% Tween 20) and mixed with an equal volume of rabbit anti-bTG antibody (at a dilution of 1 : 2000) and added to the plate. bTG standards covering the range 3.0±600 nguml were included and the assay was calibrated against the WHO 1 st International Standard Preparation for bTG (83u501). After incubation for 4 h, the plates were washed and incubated with peroxidaseconjugated anti-rabbit IgG (Jackson Labs) (dilution 1 : 8000) for 2 h. Following washing, ABTS substrate was added and the absorbance was measured at 405 nm in a multiwell spectrophotometer and results calculated using Softmax software.
Statistical methods
Non-parametric data sets were analysed by Mann±Whitney U-test for differences in median. Data sets showing a normal distribution were analysed for differences in mean by students t-test or paired t-test. A correlation between TGFb 1 and bTG was assessed using linear regression and Pearson's correlation test. Signi®cance was attributed to analyses with P-0.05.
Results

The effect of venepuncture
Ten healthy normal individuals volunteered to undergo two venepunctures on the same occasion using the special procedure (to avoid platelet activation) applied to one arm and the standard method with vacutainer (to replicate normal trauma causing platelet activation) to the other. The subsequent processing of the samples was identical to allow investigation of the effect of venepuncture trauma only. The samples were analysed for the presence of TGFb 1 and bTG, and the results are shown in Table 1 and Figure 1 . Eight of 10 samples taken under conditions that avoid platelet activation showed undetectable levels of TGFb 1 (-100 pguml) following aciduurea activation by the in-house assay (Figure 1a) . In contrast, all the paired samples taken by standard venepuncture had measurable levels of TGFb 1 (median 7.70 nguml, interquartile range 5.87±13.64 nguml). In parallel measurements of bTG (Figure 1b) in the same samples, the median value of bTG in the special samples was 0.71 mguml The two special samples that had detectable TGFb 1 also had the highest levels of bTG (4.98 and 1.70 mguml) and their paired standard samples showed the lowest increases in bTG (Figure 1b) , indicating either a signi®cant in vivo platelet activation in these normal individuals or a greater sensitivity to platelet activation on venepuncture. By expressing the results from the standard venepuncture as TGFb 1 : bTG ratio, the spuriously high TGFb 1 levels are corrected for degree of platelet activation ( Table 1 ).
The effect of immunosuppressive drugs on platelet-released TGFb 1 and bTG TGFb 1 and bTG were measured in plasma samples taken by standard venepuncture from renal transplant patients on either cyclosporine-or tacrolimus-based immunosuppressive therapy and the results are shown in Figure 2 . There was a signi®cant relationship between TGFb 1 and bTG in the sample population when analysed by Pearson's correlation test, rs0.751, P-0.0001.
There was no correlation between the platelet count and either TGFb 1 (Pearson correlation rsÀ0.067, Ps0.634) or bTG (rs0.025, Ps0.959) in these samples (data not shown).
There was a signi®cantly higher mean concentration of TGFb 1 in samples from patients on cyclosporine therapy compared with patients on tacrolimus (28 090"26 860 pguml vs 7173"10 610 pguml, respectively; students t-test P-0.002) (Figure 3a) . Mean bTG values were also higher in samples from patients on cyclosporine therapy compared with those on tacrolimus (8.14"5.45 mguml vs 3.66"3.32 mguml, respectively, students t-test P-0.002) (Figure 3b) . However, when the TGFb 1 values were corrected for the degree of platelet activation by factoring with bTG, there was no signi®cant difference in plasma TGFb 1 between patients on cyclosporine or tacrolimus (4117"2993 pgumg bTG vs 2971"658 pgumg bTG, respectively; Ps0.294) (Figure 3c ).
There was no difference in the mean absolute platelet count between patients on cyclosporine-or tacrolimus-based therapy (295"84 vs 258"72 3 10 9 ul, respectively; Ps0.113) (Figure 3d) . 
Discussion
This report documents a median plasma TGFb 1 level of 7.7 nguml (interquartile range 5.87±13.64 nguml) following aciduurea activation of the plasma samples taken by standard venepuncture from healthy controls. This is consistent with an aggregated mean of 8.1 nguml from other reported normal plasma values of 3.8 "2.9 nguml w11x, 12.2 nguml (2.2±19.3 nguml) w9x and 8.2 nguml (4.0±18.9 nguml interquartile range) w14x, where standard venepuncture has been used.
The one study carefully established to avoid platelet activation during venepuncture reports 4.1"2.0 nguml (range 2.0±12.0 nguml) w3x. However, we have demonstrated that this plasma TGFb 1 level is artefactually generated by activating platelets during the standard venepuncture procedure and therefore does not represent the in vivo circulating pool of TGFb 1 . Eight of 10 paired samples from healthy volunteers show -100 pguml TGFb 1 when precautions to reduce platelet activation are introduced. The two normal samples with the detectable level of TGFb 1 have the highest level of bTG, an accepted measure of platelet a granule secretion w12x, consistent with either in vivo platelet activation or activation despite the special procedure. Furthermore, dual measurement of TGFb 1 and bTG in 52 plasma samples from allograft recipients taken by standard venepuncture shows a signi®cant positive correlation, indicating that the degree of platelet activation either in vivo or during venepuncture determines the level of detectable TGFb 1 following activation of the sample.
Thus, deliberate sample activation prior to measurement of TGFb 1 simply reveals the quantity of latent TGFb 1 released from platelets during venepuncture. For each subject, the TGFb 1 level represents the product of their intrinsic platelet stability, the degree of trauma that these platelets suffer during venepuncture and their total platelet count. In addition to these variables, further modulation of platelet biology in vivo by disease, drug therapy, surgery, haemodialysis or ethnic in¯uences may need to be controlled. We contend that the evidence we have provided in this study supports the hypothesis that normal plasma TGFb 1 levels are undetectable (-100 pguml) if procedures are taken to minimize platelet activation.
It is valid to ask whether immunosuppressive drugs used in transplantation, in particular cyclosporine and tacrolimus, promote the expression of TGFb 1 . It is conceivable that part of their immunosuppressive action may be mediated through the potent immunosuppressive properties of TGFb 1 . Additionally, their chronic nephrotoxicity may be driven through the pro®brotic expression of TGFb 1 . Therefore, we quantitated the levels of plasma TGFb 1 in transplant patients on cyclosporine or tacrolimus using routine venepuncture and deliberate activation of the samples prior to measurement. Under these conditions, patients on cyclosporine appear initially to have higher plasma levels of TGFb 1 , compared with patients on tacrolimus. However, there are clearly increased levels of platelet activation as evidenced by increased bTG levels in the cyclosporine samples; the apparent high plasma TGFb1 levels in patients on cyclosporine merely result from greater platelet degranulation during venepuncture. This is not surprising since cyclosporine augments platelet reactivity w15,16x whereas tacrolimus does not w17,18x. Therefore, expressing the plasma results as TGFb 1 per unit of bTG identi®es no difference in the plasma total TGFb 1 levels in patients on cyclosporine or tacrolimus. Thus, any study claiming to show a difference in TGFb 1 levels between groups or treatments that relies on deliberate activation of the latent TGFb 1 must control for the level of platelet activation in the sample as has been previously recommended w3x. Failure to include proper controls for platelet activation as a source of circulating TGFb 1 has resulted in a claim that cyclosporine stimulates in vivo TGFb 1 expression w5x. Yet this effect is arguably no more than that demonstrated in this paper, i.e. that cyclosporine renders platelets more sensitive to secretion of a granule proteins such as bTG and TGFb 1 when subjected to the stress of venepuncture. Similarly, a study suggesting that ethnic differences in rates of ESRF are dependent on overexpression of TGFb 1 has not controlled for differential platelet activation between the groups, resulting in artefactual secretion of TGFb 1 . It is established that patients in ESRF on chronic haemodialysis show enhanced platelet activation w19x. Therefore, this apparent ethnic difference in expression of TGFb 1 may simply re¯ect uncontrolled effects on platelet activation caused by different patterns of haemodialysis and prescription of anti-hypertensive drugs w20x.
In order to ensure meaningful data on circulating TGFb 1 levels, the ideal strategy is the adoption of the rigorous procedures necessary to avoid platelet activation during venepuncture as described by workers in the ®eld of platelet biology w12x. To date, only one study of TGFb 1 has adopted these precautions w3x and they claim that there is a low level of circulating TGFb 1 from a non-platelet derived pool. These authors advocate strongly the use of a platelet release marker correction factor, which we have demonstrated does control for spurious effects of drugs causing release of TGFb 1 into the blood sample. Concentrating on producing`platelet poor plasma' overlooks the variable platelet secretion of TGFb1 that has already happened during venepuncture.
We suggest that the quality and validity of interpretation of most of the clinical data on circulating TGFb 1 levels is seriously¯awed due to the failure to control for the level of platelet activation in the blood samples. The future for measurement of clinically relevant pools of TGFb 1 must be in the development of assays that quantitate the products of in vivo activated TGFb 1 which may circulate as TGFb 1 complexes. Stable complexes of TGFb 1 ±endoglin have already been described and similar complexes with other natural antagonists may exist. Understanding the role of TGFb 1 in disease pathology is an important goal that is not being helped currently by the assay of a spuriously high platelet-derived pool of TGFb 1 , as if it represented a real in vivo circulating pool of TGFb 1 .
